(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2021-09-02±³À°ÀÏÀÚ : 2021-09-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° (½Ç½Ã°£ È»ó ±³À°)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °ÇØÁø
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï : ȸ¿ø(±³¼ö,Àü¹®ÀÇ,ÀüÀÓÀÇ) -> 5¸¸¿ø ºñȸ¿ø -> 7¸¸¿ø/ ȸ¿ø(Àü°øÀÇ,°£È£»ç,¾à»ç,±ºÀÇ°ü) -> 3¸¸¿ø, ºñȸ¿ø ->5¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 09:00~09:25 Different tumour sequencing strategies in different clinical settings Lillian L. Siu(Princess Margaret Cancer Centre)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 09:25~09:50 Promise and pitfall in tissue-agnostic clinical trial designs?? Vivek Subbiah(The University of Texas MD Anderson Cancer Center)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 09:50~10:15 Challenges in clinical decision-making based on sequencing data? ¹Ú°æÈ(°í·Á´ëÇб³ ¾È¾Ïº´¿ø)
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀÎ 10:15~10:30 Panel Discussion -(-)
ÈÞ½Ä 09-02 ½Ç½Ã°£¿Â¶óÀÎ 10:30~10:50 ()
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 10:50~11:30 Overcoming resistance to checkpoint blockade immunotherapy Jedd WOLCHOK(MSKCC)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 11:30~12:10 The optimal treatment strategy of mNSCLC patients in the First-line Shirish Gadgeel(University of Michigan)
ÈÞ½Ä 09-02 ½Ç½Ã°£¿Â¶óÀÎ 12:10~12:40 ()
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 12:40~13:05 Analysis of ctDNA À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 13:05~13:30 Introduction of ctDNA panels in Korea? °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 13:30~13:55 Clinical impact of ctDNA results and perspective Sarat CHANDARLAPATY(MSKCC)
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀÎ 13:55~14:10 Panel Discussion -(-)
ÈÞ½Ä 09-02 ½Ç½Ã°£¿Â¶óÀÎ 14:10~14:30 ()
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 14:30~14:50 Current status and future perspectives of immunotherapy for gastric cancer À̱ٿí(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 14:50~15:10 Evolution of anti-HER2 therapy for gastric cancer Kohei SHITARA(National Cancer Center Hospital East)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 15:10~15:30 Promising new treatments in advanced GIST ±èÈ¿¼Û(¼¼ºê¶õ½ºº´¿ø)
ÈÞ½Ä 09-02 ½Ç½Ã°£¿Â¶óÀÎ 15:30~15:50 ()
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 15:50~16:12 How to select and incooperate adequate biomarkers into clinical trials Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 16:12~16:34 How to conduct biomarker driven multi-center clinical trials : networking, logistics, feasibility Yoshiaki NAKAMURA(National Cancer Center Hospital East)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 16:34~16:56 Development of biomarker of IO with clinical trials ¾È¸íÁÖ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 16:56~17:18 Pharmacogenomics for biomarker of toxicities in oncology field Akinobu HAMADA(National Cancer Center Research Institute)
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀÎ 17:18~17:20 Q&A ()
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀÎ 17:20~18:00 Sharing experiences and establishment of guidelines of cancer care in COVID-19 pandemic Giuseppe CURIGLIANO(University of Milano)